PTN was delisted from NYSE American in May 2025 and moved to OTCQB trading, while simultaneously showing severe financial deterioration with stockholders' equity plummeting to -$4.8M and cash declining 73%.
The delisting to OTC markets significantly reduces liquidity and institutional investor access, while the negative stockholders' equity indicates the company is technically insolvent. The strategic pivot away from male sexual dysfunction treatments toward obesity-focused MC4R agonists suggests management is abandoning previous clinical programs, creating execution risk for the new direction.
PTN's financial position deteriorated dramatically with stockholders' equity falling 4,185% to negative $4.8M and cash reserves declining 73% to just $2.6M, indicating severe liquidity stress. While the company reduced operating losses by 42% through significant cost-cutting in R&D (-33.5%) and SG&A (-36.4%) expenses, total assets collapsed 70% and the company now operates with negative book value. The improved loss metrics reflect aggressive expense reduction rather than operational improvement, and the cash burn rate suggests limited runway without additional financing.
Equity declined sharply — large losses, buybacks, or write-downs reducing book value significantly.
Cash declined 73.1% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
Current assets declined 70.1% — monitor working capital adequacy and short-term liquidity.
Total assets contracted 69.6% — asset sales, write-downs, or balance sheet optimization underway.
Net income grew 41.8% — bottom-line growth signals improving overall business health.
SG&A reduced 36.4% — improved cost efficiency or headcount reduction improving operating margins.
R&D spending cut 33.5% — could signal cost discipline or concerning reduction in innovation investment.
Operating cash flow surged 32.3% — exceptional cash generation, highest quality earnings signal.
Liabilities reduced 25.9% — deleveraging improves balance sheet strength and financial flexibility.
Operating income improving — cost discipline or growing revenue base absorbing fixed costs.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →